louis vuitton for sale"Melanoma patients are living longer and better with these new treatments."However, although the study participants were described as being "typical" patients with advanced melanoma, the investigation's findings are tempered by the fact that it was not a randomized clinical trial and did not compare the impact of nivolumab directly against the performance of other drugs."[But] while this was not a randomized clinical trial, it had a considerable number of patients and the durability of responses is a sign of very promising clinical activity," Sznol said in the news release.A randomized phase III trial has begun, aimed at confirming these initial findings.Another expert agreed that the drug shows the promise of immunotherapies in general."The results of this study are truly remarkable and demonstrate that immunotherapy truly can make the difference for many melanoma patients,&quo